Welcome to our dedicated page for Sernova Biotherapeutics news (Ticker: SEOVF), a resource for investors and traders seeking the latest updates and insights on Sernova Biotherapeutics stock.
Sernova Biotherapeutics reports developments tied to its clinical-stage regenerative medicine programs, including the Cell Pouch Bio-hybrid Organ being developed for type 1 diabetes. Company news centers on clinical and regulatory updates, research collaborations involving donor cells, stem-cell derived islet-like clusters and immunosuppression approaches, and the advancement of its bio-hybrid organ platform.
Recurring updates also cover Sernova's capital structure, including private placements, debt settlements, convertible debentures, warrant issuances and debt-to-equity conversions. Governance items include annual meeting results, board composition and shareholder voting matters.
Sernova Corp (TSX: SVA, OTCQB: SEOVF) announced key strategic initiatives, including a non-binding letter of intent with HealthGena and GOLDTRACK Ventures for 'Project REEM Ventures' to explore product development and commercialization opportunities in Saudi Arabia for type 1 diabetes treatment. The company also welcomed Dr. Robert Gabbay, former Chief Scientific and Medical Officer at the American Diabetes Association, as a clinical advisor. Sernova will host a virtual Town Hall on December 13 and hold its Annual General Meeting on January 7, 2025. The company is developing a Cell Pouch bio-hybrid organ as a potential functional cure for type 1 diabetes and thyroid disorders.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) has announced positive interim data from its ongoing Phase I/II clinical trial of the Cell Pouch Transplant System for type 1 diabetes (T1D). The trial shows sustained insulin independence in all 6 patients of Cohort A after islet transplantation. Notably, histological data from a patient's explanted Cell Pouch after 5+ years revealed abundant, well-vascularized, functioning islets producing insulin, glucagon, and somatostatin. The Cell Pouch demonstrated no evidence of fibrosis or degradation after long-term implantation. Sernova plans to complete Cohort B soon and initiate Cohort C with an optimized immune suppression regimen. The company is also developing iPSC-derived islet-like clusters with partner Evotec for a scalable cell source.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF), a clinical-stage biotech company focusing on regenerative medicine cell therapies, has appointed Jonathan Rigby as its new CEO. Rigby, a type 1 diabetic himself, brings extensive experience in raising capital, leading biotech companies to Nasdaq listings, and achieving strategic acquisitions. The Board believes Rigby's leadership will position Sernova to achieve its strategic milestones.
Rigby's background includes several CEO roles and board positions in biotech companies, particularly in the diabetes field. He holds a degree in biological sciences and an MBA. The appointment aims to drive Sernova's growth and realize its full potential in developing treatments for chronic diseases, including its ongoing phase 1/2a clinical trial in type 1 diabetes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.